FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Hold Opinion On Shares Of Quebecor, Inc.

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target by CAD10 to CAD70, applying an EV/EBITDA multiple of 8.4x to our 2026 estimate, comparable to its 3-year historical average multiple at 8.1x. We increase our 2026 EPS estimate by CAD0.11 to CAD4.29 and raise 2027's by CAD0.13 to CAD4.67. The media segment continues to face a deep structural crisis, characterized by challenges such as the dominance of large players in the advertising market, declining television subscriptions, reduced support from the Canadian media fund, unfair competition from public broadcasters, and a heavy regulatory burden from the CRTC. These factors undermine private broadcasters and threaten the viability of local content production and distribution. The wireless market experienced an aggressively promotional environment, leading to unsustainable pricing and heightened competition. This environment resulted in lower organic growth and net mobile additions, as the major players primarily competed for each other's customers at reduced prices.

Related Articles

Research

Research Alert: CFRA Maintains Hold Rating On Shares Of The Cooper Companies

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $21 to $63, 13.6x our FY 26 EPS estimate (up $0.02 to $4.62; FY 27 estimate up $0.01 to $5.02). Our target multiple reflects a discount to COO's one-year historical forward average of 17.2x and well below the company's 24.9x forward average over the past five years amid ongoing restructuring efforts and uncertainty about long-term strategy given the ongoing strategic business review. We also note recent tariff headwinds and market disruption from the ongoing U.S./Iran conflict. Nonetheless, we expect near-term sales and margin improvement, with recent U.S. vision business trends appearing supportive and restructuring efforts likely to improve profitability, in our view. We anticipate near 5.6% sales growth in FY 26, above the 5.1% growth seen in FY 25, while we see adjusted operating margin improvement to near 26.7% in FY 26 from 25.8%.

$COO
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Cheniere Energy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target of $304, cut $1, reflects relative valuation and DCF models. We apply an 11.5x multiple of enterprise value to projected 2027 EBITDA, above Cheniere's historical forward average, which we see as reasonable given the very real concern over interrupted natural gas cargoes out of Qatar, a key competitor of Cheniere's. On this basis, we estimate a value of $280 per share. Meanwhile, our DCF model, using medium-term FCF growth of 6% per year, terminal growth of 2.5%, and discounted at a WACC of 6.8%, yields a value of $334 per share. We raise our 2026 EPS estimate by $4.42 to $18.90 and our 2027 EPS estimate by $1.90 to $16.19. The Strait of Hormuz remains a massive energy bottleneck, and physical damage to Qatar's LNG export capabilities creates a window of opportunity for Cheniere. Cheniere has limited spot exposure in 2026, but this may encourage more long-term deals with Cheniere if it is seen as a more reliable supplier.

$LNG
Research

Research Alert: CFRA Lowers Rating On Shares Of Boston Scientific Corporation To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $56 from $100 on 14.4x our 2027 EPS estimate, a discount to BSX's five-year historical forward P/E average. We reduce our 2026 EPS view to $3.32 from $3.40 as we lower our quarterly estimates on margin concerns. We also lower our 2027 EPS forecast to $3.90 from $4.04. While we see healthy growth in procedures and diagnostics in the long run, we are uncertain about the near-term evolution of elective surgeries due to softening demand and weakening consumer sentiment in the U.S., which hit an all-time low in May amid a complex macroeconomic environment. At the same time, we continue to see tariffs as a considerable pressure point on the cost side, as many companies in the industry have global supply chains, while competition is intensifying between BSX, Medtronic, J&J, and Abbott, in our view. Amid these challenges coupled with margin pressures stemming from rising raw material costs and supply chain challenges, we prefer to remain on the sidelines and lower our view to Hold from Buy.

$BSX